Zogenix: Await Q2 Fintepla Revenue, LGS Approval Before Jumping Back In

Since Fintepla's launch, shares of Zogenix have continued to slide. This is, primarily, due to unimpressive Fintepla adoption two quarters in and an underperforming biotechnology sector.

Top Stock Ideas Long Ideas Zogenix: Await Q2 Fintepla Revenue, LGS Approval Before Jumping Back In By Stephen Ayers • ZGNX IPO Analysis Robinhood Is A Risk-Averse Investor's Nightmare By Noah Wilson • HOOD Long Ideas Wyndham Hotels & Resorts: Strong RevPAR And Rate Recoveries Paving The Way Forward By IncomeBent Investments • WH Long Ideas International Game Technology: This End To End Global Gaming Giant Finally Redeems Its Promise By Howard Jay Klein • IGT Quick Picks & Lists Micro Focus International: Still On A Long Road To Recovery By BOOX Research • MFGP M&A SPX FLOW Received An Offer Of $85, The Fair Value Is Higher By Monplanet Capital Management • FLOW Quick Picks & Lists Halma: A Great Business But Too Expensive By The Investment Doctor • HALMY Quick Picks & Lists Jones Lang LaSalle: Market Sentiment Vs. Fundamentals By Robert Honeywill • JLL Long Ideas Suzano's Languishing Puts It On The Value Investor's Hotlist By Valkyrie Trading Society • SUZ Long Ideas Yellow Cake: A Great Risk-Reward Among Uranium Stocks By Bang For The Buck • YLLXF More Stock Ideas »  EXCLUSIVE: 5 Precursors to Triple-Digit Gains The key to finding million-dollar stocks is surprisingly simple… But often neglected. Our Top Rated Stocks system used it to identify a "Very Bullish" stock that's among the top performers of 2021. Stay focused on these 5 factors - and you could reach your investing goals in record time. Get 3 top buys now » Download the Seeking Alpha App! Like Investing Ideas? Try our other newsletters as well. This email was sent to you because you signed up to receive Investing Ideas. If you do not want to receive Investing Ideas emails, click here to unsubscribe. Sent by Seeking Alpha, 52 Vanderbilt Avenue, 13th floor, New York, NY 10017